Alvotech Participates in Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Alvotech will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, meeting with investors and Dr. Balaji Prasad, Chief Strategy Officer, participating in a fireside chat. A live webcast of the fireside chat will be available on the Alvotech website. Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025. The company will conduct investor meetings on September 9, followed by a fireside chat featuring Dr. Balaji Prasad, Chief Strategy Officer, on September 10 at 10:45 am EDT. The fireside chat will be publicly accessible via webcast on Alvotech's investor relations website, with a 90-day replay period available after the event [1].

Dr. Balaji Prasad will provide insights into Alvotech's strategic direction, market opportunities, and future prospects. The fireside chat will be an opportunity for investors and the public to gain a deeper understanding of the company's vision and progress in the biosimilar space. The webcast will be available at https://investors.alvotech.com/events/event-details/morgan-stanley-23rd-annual-global-healthcare-conference-new-york [1].

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The company seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities [1].

Alvotech has launched two biosimilars and has a development pipeline that includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company has formed strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East [1].

Recent Performance
Alvotech's shares have experienced significant volatility over the past year. In 2024, ALVO shares delivered a 15.2% rally, but by mid-2025, the stock tumbled 31.9% for the year while the S&P 500 squeaked out a 1.7% gain [2]. The company's revenue shot up 426.8% in 2024, reaching $491.98 million from $93.38 million in 2023. The main fuel behind this growth was the strong launch of AVT02 and AVT04 in the US and Europe [2].

Looking ahead, Alvotech has a diversified pipeline including new biosimilars based on Keytruda (AVT32), Xolair (AVT23), and Eylea (AVT06/AVT29) – these should help deliver fresh revenue bumps as new approvals and partnerships drop into place [2].

References
[1] https://www.stocktitan.net/news/ALVO/alvotech-meets-investors-and-participates-in-a-fireside-chat-at-the-rndqyfj4kbzw.html
[2] https://finimize.com/content/alvo-asset-snapshot